CPET

Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis

An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica

VO2T12.5% Emerges as a Key Physiological Marker for Cardiac Performance and Treatment Efficacy in Obstructive HCM